Brief: Oragenics Provides Update On Drug Intended To Treat Concussion
16/08/2024 22:39
Aug 16 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS, INC. PROVIDES UPDATE ON ITS DRUG INTENDED TO
TREAT
CONCUSSION AND NON-COMPLIANCE WITH NYSE AMERICAN CONTINUED
LISTING STANDARDS
* ORAGENICS INC: PHASE 2 HUMAN TRIALS OF ONP-002 ARE BEING
PLANNED
WITH ANTICIPATION OF STARTING IN Q4 OF THIS YEAR
Source text for Eikon: ID:nGNX5KG3Mb
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing